| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
9,860,000 |
| Market
Cap: |
4.34(M) |
| Last
Volume: |
343,990 |
Avg
Vol: |
274,696 |
| 52
Week Range: |
$0.258 - $0.76 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Titan Pharmaceuticals is a pharmaceutical company developing therapeutics utilizing its drug delivery platform, ProNeura™, for the treatment of select chronic diseases. Probuphine is a product based on its ProNeura technology approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder (OUD). Co. is conducting non-clinical studies with a nalmefene implant for the potential treatment of OUD under a grant from the National Institutes of Health. Co. is collaborating with the Walter Reed Army Institute of Research and South West Research Institute in the early non-clinical evaluation of the ProNeura platform in malaria prophylaxis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
2,283,690 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,979,170 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
5 |
| Total Shares Sold |
0 |
0 |
3,747,968 |
3,747,968 |
| Total Sell Value |
$0 |
$0 |
$4,610,000 |
$4,610,000 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
2 |
2 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Beebe Katherine |
Chief Scientific OfficerOffice |
• – – |
2019-02-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,387 |
|
- |
|
| Recli Federico Seghi |
Director |
– • – |
2018-10-19 |
4 |
B |
$0.00 |
$0 |
D/D |
200,000 |
800,845 |
2.31 |
- |
|
| Recli Federico Seghi |
Director |
– • – |
2018-09-24 |
4 |
B |
$0.00 |
$0 |
D/D |
500,000 |
600,845 |
2.31 |
- |
|
| Macfarlane M David |
Director |
– • – |
2018-09-21 |
4 |
B |
$0.25 |
$20,000 |
D/D |
80,000 |
102,275 |
2.39 |
- |
|
| Rubin Marc |
Executive Chairman |
• • – |
2018-09-21 |
4 |
B |
$0.25 |
$100,000 |
D/D |
400,000 |
556,317 |
2.81 |
- |
|
| Mcnab James R |
Director |
– • – |
2018-09-21 |
4 |
B |
$0.25 |
$50,000 |
D/D |
200,000 |
300,000 |
2.39 |
- |
|
| Akers Joseph A |
Director |
– • – |
2018-09-21 |
4 |
B |
$0.25 |
$50,000 |
D/D |
200,000 |
213,000 |
2.39 |
- |
|
| Bhonsle Sunil |
See Remarks |
• • – |
2018-09-21 |
4 |
B |
$0.25 |
$75,000 |
D/D |
300,000 |
435,578 |
2.81 |
- |
|
| Akers Joseph A |
Director |
– • – |
2016-07-19 |
4 |
B |
$4.68 |
$23,400 |
D/D |
5,000 |
13,000 |
2.39 |
- |
|
| Akers Joseph A |
Director |
– • – |
2016-07-18 |
4 |
B |
$4.95 |
$39,600 |
D/D |
8,000 |
8,000 |
2.39 |
- |
|
| Bhonsle Sunil |
President and CEO |
• • – |
2016-07-18 |
4 |
B |
$4.96 |
$49,550 |
D/D |
10,000 |
135,578 |
2.81 |
- |
|
| Mcnab James R |
Director |
– • – |
2016-05-31 |
4 |
B |
$7.03 |
$140,600 |
I/I |
20,000 |
100,000 |
2.1 |
- |
|
| Bhonsle Sunil |
President and CEO |
• • – |
2016-02-22 |
4 |
B |
$3.56 |
$41,817 |
D/D |
11,763 |
125,578 |
2.81 |
- |
|
| Bhonsle Sunil |
President and CEO |
• • – |
2016-01-15 |
4 |
B |
$2.72 |
$15,888 |
D/D |
5,841 |
113,815 |
2.81 |
- |
|
| Mcnab James R |
Director |
– • – |
2016-01-13 |
4 |
B |
$3.16 |
$51,707 |
I/I |
16,363 |
80,000 |
2.1 |
- |
|
| Rubin Marc |
Executive Chairman |
• • – |
2016-01-11 |
4 |
B |
$3.25 |
$16,250 |
D/D |
5,000 |
156,317 |
2.81 |
- |
|
| Bhonsle Sunil |
President and CEO |
• • – |
2016-01-11 |
4 |
B |
$3.18 |
$54,060 |
D/D |
17,000 |
107,974 |
2.81 |
- |
|
| Bhonsle Sunil |
President |
• • – |
2015-10-01 |
4 |
B |
$3.99 |
$798 |
D/D |
200 |
90,974 |
2.73 |
- |
|
| Bhonsle Sunil |
President |
• • – |
2015-09-30 |
4 |
B |
$3.98 |
$1,990 |
D/D |
500 |
90,774 |
2.73 |
- |
|
| Bhonsle Sunil |
President |
• • – |
2015-09-28 |
4 |
B |
$3.62 |
$3,296 |
D/D |
910 |
90,274 |
2.73 |
- |
|
| Bhonsle Sunil |
President |
• • – |
2015-09-16 |
4 |
B |
$0.70 |
$3,500 |
D/D |
5,000 |
491,500 |
2.73 |
- |
|
| Bhonsle Sunil |
President |
• • – |
2015-09-15 |
4 |
B |
$0.69 |
$3,450 |
D/D |
5,000 |
486,500 |
2.73 |
- |
|
| Rubin Marc |
Executive Chairman |
• • – |
2015-08-28 |
4 |
B |
$0.72 |
$35,750 |
D/D |
50,000 |
832,200 |
2.81 |
- |
|
| Bhonsle Sunil |
President |
• • – |
2015-08-25 |
4 |
B |
$0.70 |
$34,800 |
D/D |
50,000 |
481,500 |
2.81 |
- |
|
| Mcnab James R |
Director |
– • – |
2014-11-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
350,000 |
|
- |
|
131 Records found
|
|
Page 2 of 6 |
|
|
